^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
GEN1160
i
Other names: GEN1160, PRO1160, GEN-1160, PRO-1160, PRO 1160, GEN 1160
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Genmab
Drug class:
Topoisomerase I inhibitor, CD70-targeted antibody-drug conjugate
Related drugs:
1year
Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies (SITC 2023)
PK, immunogenicity, and antitumor activity will also be evaluated. The study is currently enrolling at sites in the US, with future enrollment in China planned.
Clinical • P1/2 data • Metastases
|
CD70 (CD70 Molecule)
|
GEN1160
over1year
Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies (KCRS 2023)
No abstract available
Clinical • P1/2 data • Metastases
|
CD70 (CD70 Molecule)
|
GEN1160
almost3years
PRO1160, a novel CD70-directed antibody-drug conjugate, demonstrates robust anti-tumor activity in mouse models of renal cell carcinoma and non-Hodgkin lymphoma (AACR 2022)
PRO1160 has the potential for an expanded therapeutic index. PRO1160 is being developed for the potential treatment of patients with CD70-expressing hematologic and solid tumor cancers.
Preclinical
|
CD70 (CD70 Molecule)
|
CD70 expression
|
GEN1160
Share via
